Adaptive Biotechnologies reported a net loss of $57.2 million for the first nine months of 2026, compared to a $45.9 million loss in the prior year period, impacted by a $23.7 million loss on revenue interest liability extinguishment. Despite the year-to-date loss, the company achieved a quarterly net income of $2.9 million in Q3 2026, though revenue for the quarter decreased to $83.9 million from $94.0 million year-over-year.
Adaptive Biotechnologies reported Q3 2026 financial results, achieving total company profitability ahead of expectations with $83.9 million in revenue and $2.8 million in net income. The company saw 44% growth in core MRD revenue (excluding milestones) and increased its full-year 2026 MRD revenue guidance. Management highlighted momentum in clonoSEQ testing and updated clinical guidelines for multiple myeloma as key growth drivers.
Term
Q3 2026
“Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue. This momentum supports another increase in our full year outlook. Updated guidelines and a new definition of cure for multiple myeloma amplify the need for MRD testing and bolster clonoSEQ’s long-term potential.”
Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies